NBIX vs SPIR · P/E 45, rev $2.36B vs rev $110.5M
Neurocrine Biosciences Inc (NBIX) versus Spire Global Inc (SPIR) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Spire Global Inc (SPIR) is a specialty business services company listed on US.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported SPIR revenue for 2024-12-31 was $110.5M. Net income was -$102.8M. Revenue was up 13.2% from 2023-12-31 to 2024-12-31. SPIR currently screens at market cap $351.2M.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. SPIR currently screens at market cap $351.2M.
Not investment advice. Open the NBIX and SPIR stock pages for the full models.
Not investment advice.